WMA
ALXN

Wealth Management Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealth Management Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,870
Closed -$328K – 182
2020
Q3 		$328K Buy
2,870
+590
+26% +$63.6K 0.25% 99
2020
Q2 		$256K Hold
2,280
– – 0.22% 112
2020
Q1 		$205K Buy
2,280
+229
+11% +$22.5K 0.21% 110
2019
Q4 		$222K Hold
2,051
– – 0.16% 138
2019
Q3 		$201K Buy
+2,051
New +$231K 0.16% 141

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wealth Management Associates's ALXN Position: Q4 2020 in Review

Wealth Management Associates sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 2,870 shares — an estimated $328K sold.

Wealth Management Associates first reported a position in ALXN in Q3 2019 and held it in 5 quarters. The position peaked at $328K in Q3 2020. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Wealth Management Associates reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Wealth Management Associates sold 2,870 Alexion Pharmaceuticals shares in Q4 2020, an estimated $328K.
  • Wealth Management Associates first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 5 quarters.
  • Wealth Management Associates's Alexion Pharmaceuticals position peaked at $328K in Q3 2020.
  • 824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Wealth Management Associates's 13F filing for Q4 2020, filed 28 May 2025.